Treatment Approach in Stage III NSCLC

 

2023 Texas Lung Cancer Conference Coverage
S

When Is PD(L)1 Monotherapy for NSCLC Enough?

By 2023 Texas Lung Cancer Conference Coverage FEATURING Shirish Gadgeel
By 2023 Texas Lung Cancer Conference Coverage FEATURING Shirish Gadgeel
40 views
June 5, 2023
0 Comments
Login to view comments. Click here to Login
Treatment Approach in Stage III NSCLC
09:40
John Conibear

PACIFIC Trial 5-Year OS Data: Clinical Implications in NSCLC

10:51
Winship Cancer Institute - Emory University

Optimising Chemoradiation to Reduce Pneumonitis Risk in Patients Wit…

Feat. N. McCall
10:47
Giulia Pasello

The Multidisciplinary Approach in Stage III NSCLC Over 10 Years: Fro…

12:40
Yale Cancer Center

Consolidation IO Following CRT in Stage III NSCLC

Feat. H. Park
15:01
OncoAlert

Radiation Oncology 2022: Advances in NSCLC

Feat. H. Willers, A. Wisdom
09:13
Federico Cappuzzo

New Options in Stage III NSCLC

12:41
Lung Cancer Europe (LuCE)

Unresectable Stage III NSCLC: Key Findings

Feat. J. Naidoo
14:23
IASLC Targeted Therapies of Lung Cancer 2023 Conference Coverage

Updates on the Use of Consolidation IO in NSCLC Based on Biomarker S…

Feat. E. Vokes
41:16
Total Health

2023 Case-Based Clinical Updates in Lung Cancer

Feat. N. Seetharamu
22:46
2023 Texas Lung Cancer Conference Coverage

When Is PD(L)1 Monotherapy for NSCLC Enough?

Feat. S. Gadgeel
23:36
CHEST 2022 Coverage

Immune Checkpoint Inhibitor Pneumonitis in Lung Cancer

Feat. J. Possick
19:41
Balazs Halmos

How I Manage Immune Adverse Events in Solid Tumors

13:19
IASLC Targeted Therapies of Lung Cancer 2023 Conference Coverage

Duration of Immunotherapy Beyond 2 Years for Patients With Advanced …

Feat. E. Rodriguez
37:21
Moffitt Cancer Center

Managing Immunotherapy-Related Adverse Events

Feat. K. Hendrix, S. Logan
17:57
2023 Texas Lung Cancer Conference Coverage

Advantages of Chemoimmunotherapy for NSCLC

Feat. M. Johnson
07:58
Janeesh Sekkath Veedu

Survival Outcomes of Surgery-Based Treatment or Definitive CRT With …

20:34
2023 Texas Lung Cancer Conference Coverage

Current Role of Adjuvant IO in NSCLC

Feat. J. Donington
16:36
Fox Chase Cancer Center

Adjuvant Therapy for Resectable NSCLC: State of the Art

Feat. M. Edelman
08:55
Insights from 2023 ASCO® Annual Meeting

Surgical Aspects in the Treatment of Locally Advanced NSCLC

Feat. G. Veronesi
08:05
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "ARC-7: Randomized Phase 2 Study of Domvan…

Feat. M. Johnson